Poly Medicure Limited carries a market capitalization of 170.72B, placing it among publicly traded companies globally. Its enterprise value stands at 115.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 170.72B |
| Enterprise Value | 115.34B |
Poly Medicure Limited currently has 101.36M shares outstanding.
| Shares Outstanding | 101.36M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Poly Medicure Limited trades at a trailing price-to-earnings ratio of 37.43. The price-to-sales ratio is 6.40, and the price-to-book ratio stands at 236.98.
| PE Ratio | 37.43 |
| PS Ratio | 6.40 |
| PB Ratio | 236.98 |
| P/TBV Ratio | 4.43 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
On an enterprise value basis, Poly Medicure Limited trades at an EV/EBITDA multiple of 67.67 and an EV/FCF ratio of 840.48. The EV/Sales ratio of 6.15 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 67.67 provides insight into valuation relative to core operating earnings.
| EV / Sales | 6.15 |
| EV / EBITDA | 67.67 |
| EV / EBIT | 67.67 |
| EV / FCF | 840.48 |
Poly Medicure Limited maintains a current ratio of 3.37, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.23, indicating elevated leverage, while an interest coverage ratio of 9.32 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 3.37 |
| Quick Ratio | 1.52 |
| Debt / Equity | 11.23 |
| Debt / EBITDA | 2.07 |
| Interest Coverage | 9.32 |
Poly Medicure Limited posts a return on equity of 57.56 and a return on invested capital of 3.96.
| Return on Equity (ROE) | 57.56 |
| Return on Assets (ROA) | 9.03 |
| Return on Invested Capital (ROIC) | 3.96 |
| Return on Capital Employed (ROCE) | 39.57 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.10 |
Over the trailing twelve months, Poly Medicure Limited has paid 1.07B in income taxes, reflecting an effective tax rate of 24.97.
| Income Tax | 1.07B |
| Effective Tax Rate | 24.97 |
Poly Medicure Limited's stock has declined approximately -23.92756% over the past 52 weeks. The 50-day moving average sits at 1,529.73, while the 200-day moving average is 1,627.46.
| Beta (5Y) | N/A |
| 52-Week Price Change | -23.92756% |
| 50-Day Moving Average | 1,529.73 |
| 200-Day Moving Average | 1,627.46 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Poly Medicure Limited generated 18.75B in revenue and converted that into 3.21B in net income, yielding earnings per share of 31.76. EBITDA reached 1.70B, while operating income came in at 1.70B.
| Revenue | 18.75B |
| Gross Profit | 11.22B |
| Operating Income | 1.70B |
| Pretax Income | 4.27B |
| Net Income | 3.21B |
| EBITDA | 1.70B |
| EBIT | 1.70B |
| Earnings Per Share (EPS) | 31.76 |
Poly Medicure Limited holds 8.73B in cash and equivalents against 3.54B in total debt, resulting in a net debt position of 2.90B. Total book value stands at 506.80M, with working capital of 13.66B providing operational flexibility.
| Cash & Cash Equivalents | 8.73B |
| Total Debt | 3.54B |
| Net Debt | 2.90B |
| Equity (Book Value) | 506.80M |
| Book Value Per Share | 5.02 |
| Working Capital | 13.66B |
Poly Medicure Limited operates with a gross margin of 59.81, reflecting its pricing power and cost economics. The operating margin of 9.09 and net profit margin of 17.11 provide insight into operational efficiency.
| Gross Margin | 59.81 |
| Operating Margin | 9.09 |
| Pretax Margin | 22.80 |
| Profit Margin | 17.11 |
| EBITDA Margin | 9.09 |
Poly Medicure Limited's most recent stock split took place on March 24, 2017 with a 1:2 split ratio.
| Last Split Date | 3/24/2017 |
| Split Ratio | 1:2 |
Poly Medicure Limited posts an Altman Z-Score of 10.54, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.54 |